BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38034719)

  • 1. Pathological complete response to neoadjuvant lorlatinib in a patient with unresectable ALK-Positive locally advanced non-small cell lung cancer: A case report.
    Chen R; Zhao L; Zhang J; Guo L; Chen Z; Pan X; Chen W
    Heliyon; 2023 Nov; 9(11):e21582. PubMed ID: 38034719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib.
    Zhai X; Wang T; Lin Y; Zhang J; Wang Y; Wang W; Zhou Q; Zhu D
    Front Oncol; 2023; 13():1104910. PubMed ID: 37064118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.
    Wang LM; Zhao P; Sun XQ; Yan F; Guo Q
    World J Clin Cases; 2023 Aug; 11(22):5322-5328. PubMed ID: 37621597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Shih JY; Luo YH; Chang GC; Chang JW; Wang CC; Yang TY; Fang WT; Shau WY
    J Formos Med Assoc; 2024 Jan; ():. PubMed ID: 38195317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
    Li J; Liu J; Zhang G; Hu W; Wang X; Liu J
    Am J Case Rep; 2023 Nov; 24():e942150. PubMed ID: 37934724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC.
    Hashimoto H; Komori K; Kameda K; Taguchi S; Ozeki Y
    Surg Case Rep; 2022 Apr; 8(1):59. PubMed ID: 35366157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
    Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
    Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
    Yun KM; Bazhenova LA
    Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
    J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
    Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
    Nakashima K; Demura Y; Kurokawa K; Takeda T; Jikuya N; Oi M; Tada T; Akai M; Ishizuka T
    Medicine (Baltimore); 2021 Oct; 100(39):e27385. PubMed ID: 34596160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
    Felip E; Shaw AT; Bearz A; Camidge DR; Solomon BJ; Bauman JR; Bauer TM; Peters S; Toffalorio F; Abbattista A; Thurm H; Peltz G; Wiltshire R; Besse B
    Ann Oncol; 2021 May; 32(5):620-630. PubMed ID: 33639216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy.
    Liu X; Zheng Y; Mai S; Tong Y; Yang L; Huang M; Cai R
    Front Oncol; 2022; 12():1033322. PubMed ID: 36505870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement.
    Zhang C; Li SL; Nie Q; Dong S; Shao Y; Yang XN; Wu YL; Yang Y; Zhong WZ
    J Thorac Oncol; 2019 Apr; 14(4):726-731. PubMed ID: 30408570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on lorlatinib: a novel first line treatment for
    Riudavets M; Planchard D
    Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.